ENDOXAN omhulde tablet

DRUG2 trials

Sponsors

Amsterdam UMC, Universitair Medisch Centrum Groningen

Conditions

relapsed / refractory multiple myelomarelapsed/refractory multiple myeloma

Phase 2

ICON study: A phase 2 study of CC220 (iberdomide) combined with low-dose cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma (IberCd)

Not yet recruitingCTIS2023-508902-66-00

Amsterdam UMCrelapsed / refractory multiple myeloma

Target: 60Updated: 2026-01-09

Phase 3

HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma

Not yet recruitingCTIS2025-524876-43-00

Universitair Medisch Centrum Groningenrelapsed/refractory multiple myeloma

Target: 126Updated: 2026-04-29